Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michelle Modlinski

Nurse Practitioner, Psychiatric/Mental Health Novi, MI Nurse Practitioner

NPI 1578951729 CMS profile 10946236

39465 W 14 Mile Rd, Novi, MI 48377

Open in the dashboard

General payments

$7,830

415 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michelle Modlinski of Novi, MI is reported in the CMS Open Payments database as having received $7,830 across 415 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,922 105
2024 General $2,103 116
2023 General $1,782 85
2022 General $1,640 94
2021 General $383 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Modlinski
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Michelle Modlinski were reported at $1,922. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Michelle Modlinski Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $383 $166 $54–$482 $132
2022 $1,640 $195 $66–$559 $149
2023 $1,782 $233 $82–$673 $160
2024 $2,103 $236 $84–$688 $164
2025 $1,922 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,129 59 payments
  2. Alkermes, Inc. $965 47 payments
  3. ITI, Inc. $868 45 payments
  4. Teva Pharmaceuticals USA, Inc. $658 30 payments
  5. Corium, Inc. $603 44 payments
  6. Otsuka America Pharmaceutical, Inc. $387 25 payments
  7. Janssen Pharmaceuticals, Inc $385 19 payments
  8. Axsome Therapeutics, Inc. $338 12 payments
  9. Collegium Pharmaceutical, Inc. $294 11 payments
  10. Ironshore Pharmaceuticals Inc. $293 17 payments
  11. Other $1,910 106 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,482 410 payments
  2. Education $349 5 payments
Products named General payments · program years 2021–2025
  1. LYBALVI Cns $847 46 payments
  2. VRAYLAR $833 45 payments
  3. CAPLYTA $815 42 payments
  4. LYBALVI Cns $713 39 payments
  5. Azstarys $603 44 payments
  6. ARISTADA Cns $521 25 payments
  7. ARISTADA Cns $521 25 payments
  8. LYBALVI Cns $444 22 payments
  9. LYBALVI Cns $444 22 payments
  10. ARISTADA INITIO $387 18 payments
  11. Other $5,067 263 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

196

Median for Nurse Practitioner: 389

Drug cost

$18,334

Median for Nurse Practitioner: $21,885

Branded share of claims

20.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 11 $15,445
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 16 $585
Bupropion Xl Bupropion Hcl Brand 14 $571
Oxcarbazepine Generic 11 $487
Lurasidone Hcl Generic 17 $409
Sertraline Hcl Generic 23 $312
Quetiapine Fumarate Generic 11 $171
Trazodone Hcl Generic 27 $156
Hydroxyzine Hcl Generic 16 $99
Alprazolam Generic 27 $42

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$6,230

Medicare's payments for the services billed

Medicare patients

21

Average age 59

Services billed

96

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 62%
Heart failure 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Azstarys
  • Corium, Inc. $339
$339 — —
VRAYLAR
  • AbbVie, Inc. $252
$252 11 —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $252
$252 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $157
  • Lundbeck LLC $46
$203 — —
CAPLYTA
  • ITI, Inc. $195
$195 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

415 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record